R&D Pipeline

 

Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.

 

Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.

Neurodegenerative Diseases

Target
Indication
Drug Candidate

c-Abl

Parkinson, ALS

FB-101 / Discovery

c-Abl/LRRK2

Parkinson, ALS

FB418 / Discovery

c-Abl/PET

PET tracer for c-Abl therapeutic

FB610 / Discovery

Undisclosed

Neurological rare disease

1ST-106 / Discovery
Discovery
Preclinical
Phase 1

Oncology

Target
Indication
Drug Candidate

HPK1

Oncology

FB849 / Discovery

GCN2

Oncology

1ST-206 / Discovery
Discovery
Preclinical
Phase 1

Rare Diseases

Target
Indication
Drug Candidate

Undisclosed

Rett syndrome and other genetic diseases

1ST-301 / Discovery
Discovery
Preclinical
Phase 1

Platform Technology

PROJECT
PLATFORM
DESCRIPTION

1ST-501

AI Drug Discovery Engine

Drug engineering platform leveraging Medchem expertise and advanced AI technology / Discovery
Discovery
Preclinical
Phase 1